CI 1018
Alternative Names: PD 168787Latest Information Update: 25 Feb 2002
At a glance
- Originator Pfizer
- Class Antiasthmatics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 25 Feb 2002 Discontinued - Phase-II for Asthma in France (PO)
- 25 Feb 2002 Discontinued - Phase-II for Asthma in USA (PO)
- 31 Dec 2000 Phase-II clinical trials for Asthma in France (PO)